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resected PanNETs (Supplementary Table 1 and Supplementary Table 2) with an average tumour content of 82% 9 with 36 tumours classified as G1, 57 as G2, and 5 as G3. Four additional PanNETs and one colon cancer from a patient with MUTYH-associated polyposis (MAP) were sequenced to validate mutational signatures (Supplementary  Table 3 ). Matched pairs of tumour and normal DNA were used for whole-genome sequencing (WGS) (average 38× normal, 61× tumour) and high-density single nucleotide polymorphism (SNP) arrays (Supplementary Table 3) , and orthogonal testing estimated that the accuracy of somatic calls exceeded 99% (Supplementary Tables 4, 5 ). Structural rearrangements were detected by integrating discordant read pairs, soft-clipping, split read and de novo assembly of non-mapping reads 10, 11 (Supplementary Table 6 ). Copy number events were identified using genome alteration print (GAP) analysis of SNP arrays 12 and recurrent focal and arm length gains and losses using GISTIC 13 (Supplementary Table 7 ).
Mutational mechanisms in PanNET
PanNETs have a lower mutation burden (0.82 per megabase, range 0.04-4.56) than their exocrine counterpart 11 (pancreatic ductal adenocarcinoma: mean 2.64, range 0.65-28.2), with the 98 PanNETs analysed here containing 258,678 high-confidence somatic point mutations and indels. Non-negative matrix factorization 14 defined five robust mutational signatures ( 14 reported in many tumour types, deamination, APOBEC (also known as AID), BRCA and a previously undescribed signature. The germline heterozygous APOBEC3A-3B deletion, which has been implicated in APOBEC-induced mutation(s) in breast cancers 15 , appears to play a minimal role in PanNETs, as only 2 out of 13 carriers exhibited a predominant APOBEC signature (Fig. 1a) . One tumour with a highly prominent BRCA deficiency signature (more than 2 mutations per Mb), and the same widespread genomic instability pattern recently described in BRCA-deficient breast 16 , pancreatic ductal 11 , ovarian 17 and oesophageal carcinomas 10 , harboured a pathogenic germline BRCA2 mutation (Fig. 1c) .
A novel mutational signature, composed of G:C > T:A transversions, predominated in five PanNETs (range 0.2-4.2 mutations per Mb; Fig. 1a , Extended Data Fig. 2 ), which bore a known pathogenic or novel inactivating germline mutation in the base-excision-repair Pancreatic neuroendocrine tumours (PanNETs) are the second most common epithelial neoplasm of the pancreas and have a mortality rate of 60% 1 . The World Health Organization (WHO) classification, which assesses the proliferative fraction of neoplastic cells, divides PanNETs into three groups: low grade (G1), intermediate grade (G2), and high grade (G3). While G3 tumours are invariably lethal, 90% of PanNETs are grade G1 or G2. These have an unpredictable clinical course that varies from indolent to highly malignant. Our current understanding of the molecular pathology of G1 and G2 PanNETs is insufficient for their clinical management, where the challenge is to predict the aggressiveness of individual tumours in order to identify patients who will benefit from early aggressive therapy and to minimize harm from the inadvertent overtreatment of patients with indolent disease.
PanNETs are usually sporadic but also occur as part of three hereditary syndromes: multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau syndrome (VHL), and occasionally tuberous sclerosis complex (TSC) 1 . Somatic mutations of MEN1 occur in 35% of PanNETs [1] [2] [3] . Recent expression profiling and exome sequencing have highlighted the importance of activated mTOR signalling as a druggable mechanism in 14% of patients 3, 4 and, although the mTOR inhibitor Everolimus is approved by the FDA for the treatment of advanced PanNET 5 , it is not yet possible to use molecular analysis to select patients who will benefit. In addition, the apoptotic regulator DAXX or the chromatin modifier ATRX are mutated in up to 40% of PanNETs 3, 6 , where they promote alternative lengthening of telomeres (ALT) and chromosomal instability 7, 8 . Our comprehensive molecular analysis of 102 clinically sporadic PanNETs defines their molecular pathology and identifies several novel candidate mechanisms that activate mTOR signalling, including novel gene fusion events. We have uncovered an important role for germline MUTYH variants through a novel G:C > T:A mutational signature. In addition, we have identified a larger-than-anticipated germline contribution to clinically sporadic PanNETs, delineating future challenges in the clinical assessment of susceptibility.
gene MUTYH, coupled with loss of heterozygosity (LOH; Fig. 1d ). This mutational signature or pattern of biallelic MUTYH inactivation was not observed in 100 pancreatic ductal adenocarcinomas using the same analysis pipeline 11 . Germline biallelic inactivation of MUTYH causes the autosomal recessive MUTYH-associated colorectal polyposis syndrome and is associated with somatic G:C > T:A transversions in the APC gene, the driver of colorectal polyps 18 . To verify our findings, we used amplicon sequencing of MUTYH on 62 additional PanNETs and identified three tumours bearing pathogenic germline mutations coupled with LOH. Whole-genome analysis revealed that these three tumours displayed the same novel mutational signature (Fig. 1b, Extended Data Fig. 3) . Interestingly, the two missense MUTYH mutations identified in the Italian cohort (c.536A > G, p.Y179C; c.1187G > A, p.G396D) are the most common MAP-linked variants in populations of European origin and have been shown to be founder mutations in a recent haplotype analysis of 80 families with MAP from Italy and Germany
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. Finally, whole-genome sequencing of a colonic tumour from a patient with MAP confirmed that this signature indicates MUTYH deficiency (Fig. 1b, Extended  Data Fig. 3 ). These data suggest that, in addition to predisposing to colonic, gastric and a variety of non-gastrointestinal cancers 20 , MUTYH deficiency plays a role in PanNET.
Clusters of breakpoints were identified (Extended Data Fig. 4a ) in nine tumours (9%), which displayed structural variations and copy-number changes consistent with chromothripsis 21 (Supplementary Table 9 ). Four of these nine tumours had recurrent catastrophic rearrangements on chromosome 11q (Extended Data Fig. 4b ), all involving 11q13, and two of these rearrangements led to loss of MEN1. Notably, despite TP53 being considered a hallmark of chromothripsis 22 , no PanNET discovery cohort PanNET validation cohort
Splice site n = 98
Splice site n = 1 LOH MUTYH 546aa TP53 mutations were present in tumours with genomic catastrophes in PanNETs.
Germline mutations
The discovery of germline deleterious mutations in MUTYH and BRCA2 prompted us to screen the germlines of all patients for mutations in DNA damage repair genes or genes associated with hereditary syndromes (Supplementary Tables 10, 11 ). In the case of known neuroendocrine predisposition genes, six patients carried either known pathogenic or novel deleterious germline MEN1 mutations (four frameshifts, one splice site mutation, and one copy-number loss). A single novel truncating CDKN1B germline mutation was identified (Q163X). CDKN1B germline mutations cause multiple endocrine neoplasia type 4 (ref. 23) and somatic mutations occur in intestinal neuroendocrine tumours 24 . A single, novel, pathogenic germline mutation was identified within VHL, a negative regulator of hypoxia signalling that promotes neuroendocrine proliferation and PanNETs
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. In every case, germline alterations were coupled with somatic LOH.
The DNA-damage repair gene CHEK2, a known tumour suppressor in breast cancer and other cancer types, had predicted damaging germline variants in four individuals (4%): a nonsense mutation (c.58C > T, Q20X), a 15-base pair in-frame deletion (c.246-260del, p.D77-E82del), a missense mutation in exon 2 implicated in prostate cancer predisposition (rs121908702, c.844G > A, p.E282K) 26 and a missense variant in exon 4 (c.529G > C, p.D177H). Mutation modelling predicted these variants to be damaging (Extended Data Fig. 5a, b) . To investigate the functional consequences of CHEK2 mutations, we generated a panel of Flag-CHEK2 constructs encoding the wild-type, P85L, D177H, E282K and ∆ 77-82 variants. The conservative mutant P85L showed expression and kinase activity equivalent to the wild type, but cells expressing the predicted pathogenic mutants D177H, E282K and ∆ 77-82 showed low kinase activity due to a combination of reduced protein expression and kinase inactivity (both autophosphorylation and phosphorylation of the substrate CDC25C) (Extended Data Fig. 5c-j) .
Somatic driver mutations
A total of 15,751 somatic coding mutations (7,703 non-silent) were detected in 2,787 genes (Supplementary Tables 4, 5). Sixteen significantly and recurrently mutated genes were defined using IntOGen 27 analysis (Q < 0.1) (Extended Data Fig. 6a, Supplementary Table 12 ). Consistent with previous reports, MEN1 was the most frequently mutated of these genes, present in 37% of tumours (Extended Data  Fig. 6b ). Mutually exclusive inactivating mutations of DAXX and ATRX were found in 22 and 11 samples, respectively, including a structural rearrangement of ATRX. The mechanistic target of rapamycin (mTOR) pathway genes PTEN (n = 7) and DEPDC5 (n = 2) were also significantly mutated. PTEN mutations were mutually exclusive with mutations in TSC1 (n = 2) and TSC2 (n = 2), which encode other negative regulators of mTOR signalling (Supplementary Table 5 ). As mutations of the tumour suppressor gene DEPDC5 have not been previously described in PanNETs, we surveyed an additional 62 cases (Supplementary Table 14 ) and identified a further 2 tumours that harboured DEPDC5 mutations, which were again mutually exclusive to PTEN (n = 3) and TSC2 mutations (n = 3) (Supplementary Table 15 ). Consistent with the literature, deleterious TP53 mutations were uncommon (n = 3). Among the genes not meeting the significance threshold by IntOGen, the histone modifier SETD2 was mutated in five samples (Extended Data Fig. 6a, Supplementary Table 5 ). Similar to previous observations in renal cell carcinoma 28 , we observed multiple independent SETD2 mutations in presumed subclones of one tumour (a nonsense at 3%, a missense at 14% and a frameshift at 11% allelic frequency), suggesting strong selection for SETD2 inactivation in that particular tumour.
Copy number changes
Copy number analysis revealed four discrete groups of patients based on arm length copy number patterns (Extended Data Fig. 7a ). These were classified into: 1) recurrent pattern of whole chromosomal loss (RPCL); 2) limited copy number events, many of which were losses affecting chromosome 11; 3) polyploidy; and 4) aneuploidy (Extended Data Fig. 7a, b) . Notably, the RPCL subtype consistently presented loss of specific chromosomes (Extended Data Fig. 7 ) and was significantly enriched in G2 PanNETs (P = 0.0247, χ 2 test). The polyploid group had the highest somatic mutation rate (P ≤ 0.002, Mann-Whitney test) with an average of 1.98 mutations per Mb (Extended Data Fig. 7c ).
Recurrent regions of gain and loss (Supplementary Table 7 
Chromosomal rearrangements
Structural rearrangements are less common in PanNETs (mean, 29 events per tumour; range 3-216) (Supplementary Table 6 ) than in pancreatic ductal adenocarcinoma (119 per tumour; range 15-558) 11 . Inactivation of tumour suppressor genes through rearrangement occurred in MTAP (n = 4), ARID2 (n = 5), SMARCA4 (n = 3), MLL3 (n = 3), CDKN2A (n = 1), and SETD2 (n = 1). Rearrangements can also create oncogenic drivers through in-frame gene fusions. We identified 66 somatic fusions capable of expressing in-frame chimaeric genes (Supplementary Table 6 ). The EWSR1 gene was involved in fusion events in three PanNETs. Two tumours possessed in-frame EWSR1-BEND2 fusion genes, which were expressed as mRNA (Fig. 2a, b) , defining BEND2 as a novel EWSR1 fusion partner. Of note, BEND2 was recently reported to be a fusion partner of MN1
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. One tumour contained an EWSR1 exon 7-FLI1 exon 6 gene fusion confirmed by RNA sequencing (RNA-seq) (Fig. 2c) . EWSR1-FLI1 fusions occur in sarcomas 36, 37 , where EWSR1 exon 7-FLI1 exon 6 is the most common (Type I) 38 , but sarcomas rarely arise in the pancreas or gastrointestinal tract 39 . Unlike PanNET, sarcomas typically exhibit a distinctive, highgrade, undifferentiated round cell morphology along with strong membrane expression of the glycoprotein CD99. The three tumours that contained EWSR1 fusions had morphological and immuno phenotypical features typical of PanNETs, had absent or weak staining for CD99, and lacked any clinicopathological features of Ewing sarcoma. Inactivation of tumour suppressor genes (STAG2, TP53, and CDKN2A) and specific chromosomal copy-number alterations (gains of chromosome 1 and 8q), which are common in Ewing sarcomas [40] [41] [42] , were absent in these three cases. The three fusion events involved the region of EWSR1 that is most susceptible to breakage or translocation in a variety of soft tissue tumours and Ewing sarcoma, and can be detected by fluorescent in situ hybridization (FISH) using break-apart probes for EWSR1 (Fig. 2a-c) . By applying FISH to the 62 cases of the validation cohort, we identified an additional PanNET with positive split signals due to an EWSR1 exon 7-FLI1 exon 5 fusion (Type II) confirmed at the mRNA level (Fig. 2d ). This latter tumour had strong immunostaining for CD99 and mutations in MEN1, ATRX and TSC2.
Telomere integrity and PanNET molecular subtypes
Telomere repeat content was quantified using whole-genome sequencing data, and ALT was assessed using C-tailing qPCR in 86 cases (Extended Data Fig. 8a ). In total, 22 of 26 ATRX or DAXX mutant tumours displayed ALT, and in DAXX mutations were more frequent (19/22) than ATRX mutations (3/22), in contrast to in vitro studies in which ATRX alterations are more prevalent 43 . Biallelic inactivation of ATRX or DAXX through LOH was strongly associated with an increase in telomere length (P < 0.0001, Mann-Whitney test; Extended Data Fig. 8b, c) . MEN1 somatic mutations were also associated with increased telomere length (P < 0.0001, Mann-Whitney test) (Extended Data Fig. 8d, e) , suggesting that MEN1 has a role in chromosome maintenance.
To better understand the consequences of ALT, we compared somatic telomere content with copy-number and structural variation patterns (Fig. 3) . Genomic catastrophes and EWSR1 fusions were associated with short telomeres, which is consistent with observations that telomere exhaustion plays a role in chromothripsis and breakagefusion-bridge events in solid cancers. Surprisingly, tumours with ALT were strongly associated with the PanNET RPCL phenotype, with 16 out of 21 tumours with RPCL displaying ALT. Previously, ALT tumours have been reported to undergo recurrent regions of gene copy gain and loss in a panel of human cancer cell lines in vitro 43 ; in contrast, whole-chromosome loss of specific chromosomes predominates in PanNETs.
Integrated analysis of PanNET cancer pathways
RNA sequencing of 30 cases revealed 3 groups of PanNET tumours (Extended Data Fig. 9a ), which were similar to three previously described expression subtypes termed insulinoma, intermediate and metastasis-like (MLP) 44 (Extended Data Fig. 9b ). One group was similar to the intermediate subtype. The group most similar to the MLP subtype contained differential expression of genes associated with hypoxia and HIF signalling (Extended Data Fig. 9c-e) .
Four pathways were commonly altered by mutation in PanNETs. Peturbations in these pathways may potentially define clinically relevant subtypes that could be used to direct stratified therapeutic approaches (Fig. 4) : i) DNA damage repair: germline-damaging variants of the base-excision-repair MUTYH gene and the homologous recombination genes CHEK2 and BRCA2 were present in 11% of patients. ii) Chromatin remodelling: MEN1, SETD2, ARID1A and MLL3 were recurrently inactivated, and these mutations are likely to drive widespread transcriptional dysregulation. iii) Telomere maintenance: upregulation of TERT and telomere lengthening is a wellestablished pro-survival mechanism in solid tumours. MEN1 binds the a, Telomere length was estimated using whole-genome sequencing in 98 PanNETs. The relative telomere length in each tumour compared to the matched normal is shown as log 2 . Twenty-four tumours contained telomeres that were 1.5× longer than matched normal DNA and 36 contained telomeres that were 1.5× shorter than matched normal DNA.
b, Most of the tumours with long telomeres had ALT and 13 contained genomes with large amounts of whole chromosome arm losses. Somatic mutations in DAXX or ATRX were strongly associated with increased telomere length (P < 0.0001, Mann-Whitney test). Tumours with short telomeres contained fewer mutations in DAXX and ATRX and more chromothripsis events or EWSR1 gene fusions. TERT promoter and influences the machinery that controls telomere integrity 45 . Consistent with previous reports, inactivating mutations in DAXX or ATRX were present in one third of PanNETs and correlated strongly with somatic telomere repeat content and telomere length (Extended Data Fig. 8b, c) . Tumours harbouring DAXX or ATRX mutations were associated with a poor prognosis in the G2 subgroup (Extended Data Fig. 10a, b) , and correlated significantly (P= 0.0214) with mutations in mTOR regulators (Supplementary Table 13 ). Tumours with unaltered telomere length had a better outcome (Extended Data Fig. 10c ). iv) mTOR signalling activation: the role of mTOR in PanNETs has been well established 3, 4 . Inactivating mutations in negative regulators of mTOR signalling (PTEN, TSC2, and TSC1 and DEPDC5 reported here) were present in 12% of patients, and were associated with a poor prognosis in the G2 subgroup of patients (hazard ratio = 6.85, 95% confidence interval = 1.14-41.7; P = 0.0353, Supplementary Table 1 and Extended Data Fig. 10d) . These mutations may represent putative biomarkers for the selection of patients for mTOR inhibitor therapy 5 . We uncovered three potential novel mTOR pathway activation mechanisms: inactivating mutations of the tumour suppressor DEPDC5, which encodes a subunit of the GATOR1 complex, a suppressor of mTOR signalling 46 ; a putative mTOR activation mechanism involving EWSR1 fusion genes; and amplification of the RET receptor ligand PSPN.
Moreover, inactivation of MEN1, which has a broad range of functions, directly influences all these four key processes 45, [47] [48] [49] (Fig. 4) . MEN1 encodes the histone modifier Menin and its inactivation drives a variety of phenotypes including widespread transcriptional dysregulation via histone modification 49 , activation of mTOR through AKT expression 48 , suppression of homologous recombination DNA damage response genes 47 and dysregulation of TERT 45 .
Conclusion
We have described the mutational landscape of PanNETs and the mutational signatures that underlie their pathogenesis, including a previously undescribed mutational mechanism involving MUTYH inactivation. We uncovered previously undescribed mTOR pathway activation mechanisms including DEPDC5 inactivation and EWSR1 fusion events. In addition, we identified subtypes of PanNET on the basis of global copy number profiles and gene mutations that have potential clinical utility. There are three key clinical considerations that these data bring to the fore. 1) The discovery of a larger-thananticipated germline mutation contribution to PanNET development, particularly in patients without a family history, has implications for individuals that carry these mutations and have an increased but unquantifiable risk of disease.
2) The mutational status of DAXX, ATRX and mTOR pathway genes could be used to stratify the prognosis of intermediate grade (G2) PanNETs, the subgroup with the least predictable clinical behaviour. This calls for exploration of the clinical utility of this approach in prospective clinical trials.
3) The identification of previously undescribed mechanisms that activate mTOR signalling may lead to the development of biomarkers that could be used to predict therapeutic responsiveness to mTOR inhibitors such as everolimus, which are currently poorly defined.
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Figure 4 | Core pathways in PanNETs. The frequency of somatic mutations and copy number change are shown for key genes of the mTOR signalling, histone modification, altered telomere length and DNA damage repair pathways. MEN1, which is frequently mutated in PanNETs, is involved in all of these processes. Activating changes (red) include a copy number change of 6 or more and inactivating changes (blue) include copy number 1 or copy number two with LOH. Asterisks show genes that also contain germline variants predicted as pathogenic. ATRX is located on chromosome X and showed point mutations in six males and four females, and in three of the females the inactivation was biallelic by LOH. A patient criterion for admission to the study was that they were clinically sporadic. This information was acquired through direct interviews with participants and a questionnaire regarding their personal history and that of relatives with regard to pancreas cancers and any other cancers during anamnesis. Clinical records were also used to clarify familial history based on patient indications.
Samples were prospectively and consecutively acquired through institutions affiliated with the Australian Pancreatic Cancer Genome Initiative. Samples from the ARC-Net biobank are the result of consecutive collections from a single centre.
All tissue samples were processed as previously described 51 . Representative sections were reviewed independently by at least one additional pathologist with specific expertise in pancreatic diseases. Samples either had full face frozen sectioning performed in optimal cutting temperature (OCT) medium, or the ends excised and processed in formalin to verify the presence of tumour in the sample to be sequenced and to estimate the percentage of neoplastic cells in the sample relative to stromal cells. Macrodissection was performed if required to excise areas that did not contain neoplastic epithelium. Tumour cellularity was determined using SNP arrays (Illumina) and the qpure tool 9 . Sample size. PanNET is a rare tumour type and the samples were collected via an international network. We estimate that with 98 unique patients in the discovery cohort, we will achieve 90% power for 90% of genes to detect mutations that occur at a frequency of ~ 10% above the background rate for PanNET (assuming a somatic mutation frequency of more than 2 per Mb) 52 . Colon sample acquisition. Cancer and matched normal colonic mucosa were collected at the time of surgical resection from the Royal Brisbane and Women's Hospital and snap frozen in liquid nitrogen. A biallelic germline mutation in the MUTYH gene was detected by restriction fragment length polymorphism analysis and confirmed by automated sequencing to be the G382D mutation (or ENST00000450313.5 G396D, ClinVar#5294) in both alleles 53 .
Immunohistochemistry. The primary antibodies used for immunohistochemical staining were: cytokeratin 8/18 (5D3, Novocastra), chromogranin A (DAK-A3, Dako), and CD99 (O13, Biolegend). Antibodies and staining conditions have been described elsewhere 39 . Sequencing and mutation analysis. Whole-genome sequencing with 100-bp paired reads was performed with a HiSEQ2000 (Illumina). Sequence data were mapped to a GRCh37 using BWA and BAM files are available in the EGA (accession number: EGAS00001001732). Somatic mutations and germline variants were detected using a previously described consensus mutation calling strategy 11 . Mutations were annotated with gene consequence using SNPeff. The pathogenicity of germline variants was predicted using cancer-specific and locus-specific genetic databases, medical literature, computational predictions with ENSEMBL Variant Effect Predictor (VEP) annotation, and second hits identified in the tumour genome. Intogen 27 was used to find somatic genes that were significantly mutated. Somatic structural variants were identified using the qSV tool as previously described 10, 11, 17 . Coding mutations are included in supplementary tables and all mutations have been uploaded to the International Cancer Genome Consortium Data Coordination Center. Mutational signatures. Mutational signatures were predicted using a published framework 14 . Essentially, the 96-substitution classification was determined for each sample. The signatures were compared to other validated signatures and the prevalence of each signature per megabase was determined. Copy number analysis. Somatic copy number was estimated using high density SNP arrays and the GAP tool 12 . Arm level copy number data were clustered using Ward's method, Euclidian distance. GISTIC 13 was used to identify recurrent regions of copy number change. Telomere length. The whole genome sequence data was used to determine the length of the telomeres in each sample using the qMotif tool. Essentially, qMotif determines telomeric DNA content by calculating the number of reads that harbour the telomere motif (TTAGG), and then estimates the relative length of telomeres in the tumour compared to the normal. qMotif is available online (http://sourceforge.net/projects/adamajava). Telomere length was validated by qPCR as previously described 54 .
RNA-seq and analysis. RNASeq library preparation and sequencing were performed as previously described 55 . Essentially, sequencing reads were mapped to transcripts corresponding to ensemble 70 annotations using RSEM. RSEM data were normalized using TMM (weighted trimmed mean of M-values) as implemented in the R package 'edgeR' . For downstream analyses, normalized RSEM data were converted to counts per million (c.p.m.) and log 2 transformed. Genes without at least 1 c.p.m. in 20% of the sample were excluded from further analysis 55 . Unsupervised class discovery was performed using consensus clustering as implemented in the ConsensusClusterPlus R package 56 . The top 2,000 most variable genes were used as input. Differential gene expression analysis between representative samples was performed using the R package 'edgeR' 57 . Ontology and pathway enrichment analysis was performed using the R package 'dnet' 58 . PanNET class enrichment using published gene signatures 44 was performed using Gene Set Variation Analysis (GSVA) as described previously 55 . Validation of fusion transcripts. Two strategies were used to verify fusion transcripts. For verification of EWSR1-BEND2 fusions, cDNAs were synthesized using the SuperScript VILO cDNA synthesis kit (Thermofisher) with 1 μ g purified total RNA. For each fusion sequence, three samples were used: the PanNET sample containing the fusion, the PanNET sample without that fusion, and a non-neoplastic pancreatic sample. The RT-PCR product were evaluated on the Agilent 2100 Bioanalyzer (Agilent Technologies) and verified by sequencing using the 3130XL Genetic Analyzer (Life Technologies). Primers specific for EWSR1-BEND2 fusion genes are available upon request. To identify the EWSR1 fusion partner in the case ITNET_2045, a real-time RT-PCR translocation panel for detecting specific Ewing sarcoma fusion transcripts was applied as described 59 . Following identification of the fusion partner, PCR amplicons were subjected to sequencing using the 3130XL Genetic Analyzer. Fluorescent in situ hybridization analysis. EWSR1 rearrangements were assayed on paraffin-embedded tissue sections using a commercial split-signal probe (Vysis LSI EWSR1 (22q12) Dual Colour, Break Apart Rearrangement FISH Probe Kit) that consists of a mixture of two FISH DNA probes. One probe (~ 500 kb) is labelled in SpectrumOrange and flanks the 5′ side of the EWSR1 gene, extending through intron 4, and the second probe (~ 1,100 kb) is labelled in SpectrumGreen and flanks the 3′ side of the EWSR1 gene, with a 7-kb gap between the two probes. With this setting, the assay enables the detection of rearrangements with breakpoints spanning introns 7-10 of the EWSR1 gene. Hybridization was performed according to the manufacturer's instructions and scoring of tissue sections was assessed as described elsewhere 60 , counting at least 100 nuclei per slide. Mutations are highlighted by rendering as magenta sticks with protein domains coloured as indicated in the adjacent keys. The model includes a superimposed phosphopeptide (red). b, A summary of the CHEK2 variants and their predicted impact on protein structure. To functionally test the CHEK2 variants, a panel of FLAG-CHEK2 constructs encoding P85L, ∆ 77-82, D177H and E282K was generated. c, d, FLAG western blot of transfected HEK293T whole cell lysates (c) or anti-FLAG immunoprecipitates (d) showed that, compared to the wild type, there was normal expression of P85L but reduced expression of ∆ 77-82, D177H and E282K. e, Assessment of kinase activity of CHEK2 variants. Immunoprecipitated proteins were incubated either with GST alone (− ) or with GST-CDC25C amino acids 200-256 (+ ) in the presence of γ -P32 ATP. Input and kinase activity were assessed by film radiography (top) and coomassie staining (bottom). Immunoprecipitates of ∆ 77-82, D177H and E282K had significantly reduced kinase activity in terms of both autophosphorylation and phosphorylation of CDC25C whereas the activity of P85L was normal. f, Quantification of expression levels by western blotting expressed as a fraction of wild type. Data points represent independent experiments. Error bars are mean ± s.e.m. g, h, Quantification of kinase activity. P32 counts for CDC25C (g) and CHEK2 (h) bands were scintillation counted. Corresponding bands from untransfected controls were used for background subtraction. Background-corrected P32 counts per minute were then standardized to wild type for each experiment. Data points represent independent experiments. Error bars are mean ± s.e.m. i, j, Quantification of kinase activity relative to protein expression. Kinase activity (from i and j) was standardized to protein expression level (from f). D177H was not analysed in this manner owing to its very low expression level. Error bars are mean ± s.e.m. Once the low expression level of ∆ 77-82 is taken into account, it is evident that the expressed protein retains normal kinase activity. On the other hand, E282K is kinase defective even after adjusting for its reduced expression. D177H expression is so low that it is not possible to reliably correct kinase activity for relative expression level, so it is unclear whether D177H is kinase dead as well as unstable. Data are summarized in Supplementary Table 16. 
